Development of new weight loss drug supported by Novo Nordisk
A promising new weight-loss drug being developed by US pharmaceutical company Lexicon Pharmaceuticals has received a major boost from Novo Nordisk, currently the most successful manufacturer of weight-loss products.
It is an oral preparation blocking the ACSL5 protein, which comprehensively affects the regulation of fat storage and appetite.
Novo Nordisk will support the development with a total of $1 billion and in exchange will receive a licence to sell the substance.
This is the latest in a series of investments by the company in the area of weight loss products and complements its current portfolio, led by the subcutaneously administered drug semaglutide, which has a proven effect on diabetes control, weight reduction and reducing the risk of cardiovascular events.
